2026-05-13

Wheat volume spike — 6.2× the 20-day average (130,493 vs 21,180 avg)

Copper volume spike — 25.8× the 20-day average (58,029 vs 2,246 avg)

Silver volume spike — 28.3× the 20-day average (52,628 vs 1,856 avg)

Gold volume spike — 204.9× the 20-day average (111,769 vs 545 avg)

Platinum volume spike — 324.2× the 20-day average (18,772 vs 57 avg)

Coffee volume spike — 8.2× the 20-day average (12,561 vs 1,529 avg)

Cocoa volume spike — 14.6× the 20-day average (25,336 vs 1,730 avg)

OSINT: US Cancels 4,000‑Troop Deployment to NATO Eastern Front

RBOB Gasoline bear 6.5% vs prior close ($3.70 → $3.46)

OSINT: US-China Summit to Address Iran, Taiwan, AI, Trade and Agriculture

OSINT: Russian Deposit Activity Surges Amid Economic Pressures

OSINT: Three VLCCs Load 6M Barrels of Crude at Iran's Kharg Island

Oil +4.06% — significant rally

Heating Oil bear 4.8% vs prior close ($4.16 → $3.96)

Cotton volume spike — 2.3× the 20-day average (26,831 vs 11,858 avg)

Coffee bear 4.8% vs prior close ($294.80 → $280.70)

Oil -1.30% — significant selloff

ETH ETF inflow of $250M — institutional buying

BTC ETF inflow of $109M — institutional buying

BTC ETF inflow of $109M — institutional buying

ETH ETF inflow of $250M — institutional buying

ETH ETF inflow of $250M — institutional buying

BTC ETF inflow of $109M — institutional buying

SOL DEX volume/liquidity ratio elevated (1.05x) — strong on-chain trading activity

Debt issued for acquisition financing — deal likely imminent

FDA approves DIFLUCAN (Pfizer) — new revenue stream

FDA approves DIFLUCAN (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves TESTOSTERONE CYPIONATE (Pfizer) — new revenue stream

FDA approves PRAZOSIN HYDROCHLORIDE (Pfizer) — new revenue stream

FDA approves PRAZOSIN HYDROCHLORIDE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves DIFLUCAN (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves DISOPYRAMIDE PHOSPHATE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves TESTOSTERONE CYPIONATE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves PRAZOSIN HYDROCHLORIDE (Pfizer) — new revenue stream

FDA approves TESTOSTERONE CYPIONATE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves DISOPYRAMIDE PHOSPHATE (Pfizer) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves CREON (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves SAVELLA (AbbVie) — new revenue stream

FDA approves NAMZARIC (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves SAVELLA (AbbVie) — new revenue stream

FDA approves NAMZARIC (AbbVie) — new revenue stream

FDA approves CREON (AbbVie) — new revenue stream

FDA approves ORILISSA (AbbVie) — new revenue stream

FDA approves ORILISSA (AbbVie) — new revenue stream

FDA approves PRED MILD (AbbVie) — new revenue stream

FDA approves SAVELLA (AbbVie) — new revenue stream

FDA approves CREON (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves NAMZARIC (AbbVie) — new revenue stream

FDA approves PRED MILD (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves PRED MILD (AbbVie) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

Debt issued for acquisition financing — deal likely imminent

FDA approves UNASYN (Pfizer) — new revenue stream

FDA approves UNASYN (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (Pfizer) — new revenue stream

FDA approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (Pfizer) — new revenue stream

FDA approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (Pfizer) — new revenue stream

FDA approves UNASYN (Pfizer) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves ALPHAGAN P (AbbVie) — new revenue stream

FDA approves ZYMAXID (AbbVie) — new revenue stream

FDA approves ZYMAXID (AbbVie) — new revenue stream

FDA approves ALPHAGAN P (AbbVie) — new revenue stream

FDA approves ALPHAGAN P (AbbVie) — new revenue stream

FDA approves ZYMAXID (AbbVie) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

Debt issued for acquisition financing — deal likely imminent

CNC job postings down -91% WoW — potential restructuring

Ameriprise Financial search volume spiked +83 pts — unusual interest

OSINT: BT's high-price broadband contract sparks consumer backlash

Amgen search volume spiked +81 pts — unusual interest

Alphabet Inc. (Class A) search volume spiked +100 pts — unusual interest

Altria search volume spiked +78 pts — unusual interest

5 congress members traded TDG — net BEAR (0B/0S)

Missed consensus by 8.2% — EPS $0.58 vs $0.6316 estimate

Beat consensus by 5.7% — EPS $11.44 vs $10.8277 estimate

Beat consensus by 49.8% — EPS $12.89 vs $8.6063 estimate

Beat consensus by 21.0% — EPS $11.83 vs $9.78 estimate

Beat consensus by 7.4% — EPS $0.68 vs $0.6334 estimate

Beat consensus by 15.3% — EPS $0.68 vs $0.5896 estimate

Beat consensus by 11.8% — EPS $3.6 vs $3.2191 estimate

Beat consensus by 6.1% — EPS $4.38 vs $4.1275 estimate

Beat consensus by 27.7% — EPS $0.82 vs $0.642 estimate

Beat consensus by 9.2% — EPS $0.73351 vs $0.6715 estimate

Beat consensus by 14.8% — EPS $1.08 vs $0.9411 estimate

Missed consensus by 6.1% — EPS $1.23 vs $1.3103 estimate

Beat consensus by 9.4% — EPS $1.34 vs $1.2251 estimate

Beat consensus by 5.8% — EPS $1.4 vs $1.3228 estimate

Beat consensus by 28.7% — EPS $2.68 vs $2.082 estimate

Beat consensus by 26.4% — EPS $2.69 vs $2.1278 estimate

Beat consensus by 21.6% — EPS $1.92 vs $1.5794 estimate

Beat consensus by 34.3% — EPS $1.64 vs $1.2213 estimate

Beat consensus by 51.3% — EPS $3.47 vs $2.2935 estimate

Beat consensus by 15.2% — EPS $2.52 vs $2.1881 estimate

Beat consensus by 38.1% — EPS $2.38 vs $1.7233 estimate

Beat consensus by 13.0% — EPS $2.47 vs $2.186 estimate

Beat consensus by 221.3% — EPS $0.49 vs $-0.404 estimate

Missed consensus by 131.1% — EPS $-0.12 vs $0.3853 estimate

Beat consensus by 25.7% — EPS $0.46 vs $0.366 estimate

Beat consensus by 51.8% — EPS $0.23 vs $0.1515 estimate

Missed consensus by 1279.3% — EPS $-0.12 vs $-0.0087 estimate

Beat consensus by 12.4% — EPS $2.71 vs $2.411 estimate

Missed consensus by 31.9% — EPS $1.76 vs $2.5831 estimate

Beat consensus by 10.4% — EPS $3.58 vs $3.2413 estimate

Beat consensus by 15.4% — EPS $3.61 vs $3.1286 estimate

Beat consensus by 14.1% — EPS $4.26 vs $3.7323 estimate

Missed consensus by 17.1% — EPS $0.32 vs $0.386 estimate

Missed consensus by 5.5% — EPS $1.51 vs $1.5978 estimate

Missed consensus by 15.7% — EPS $0.84 vs $0.9965 estimate

Beat consensus by 6.5% — EPS $1.24 vs $1.1643 estimate

Beat consensus by 16.2% — EPS $1.42 vs $1.2221 estimate

Beat consensus by 23.7% — EPS $1.17 vs $0.9458 estimate

Beat consensus by 7.7% — EPS $3.39 vs $3.1472 estimate

Beat consensus by 217.1% — EPS $0.13 vs $0.041 estimate

Beat consensus by 2331.4% — EPS $0.27 vs $-0.0121 estimate

Beat consensus by 7.2% — EPS $3.85 vs $3.5928 estimate

Beat consensus by 14.6% — EPS $4.88 vs $4.2594 estimate

Beat consensus by 6.4% — EPS $4.35 vs $4.0901 estimate

Beat consensus by 22.2% — EPS $0.21 vs $0.1718 estimate

Beat consensus by 15.8% — EPS $0.33 vs $0.2849 estimate

Beat consensus by 6.5% — EPS $0.25 vs $0.2348 estimate

Beat consensus by 13.9% — EPS $0.16 vs $0.1405 estimate

Beat consensus by 28.3% — EPS $1.05 vs $0.8181 estimate

Beat consensus by 22.6% — EPS $0.82 vs $0.6686 estimate

Beat consensus by 117.6% — EPS $1.49 vs $0.6848 estimate

Beat consensus by 11.4% — EPS $2.4 vs $2.1545 estimate

Missed consensus by 10.0% — EPS $2.56 vs $2.8434 estimate

Beat consensus by 5.8% — EPS $7.22 vs $6.8247 estimate

Beat consensus by 5.1% — EPS $7.69 vs $7.3172 estimate

Beat consensus by 9.1% — EPS $4.88 vs $4.4716 estimate

Missed consensus by 20.4% — EPS $4.05 vs $5.0878 estimate

Missed consensus by 5.4% — EPS $2.1 vs $2.2193 estimate

Beat consensus by 8.4% — EPS $2.16 vs $1.9927 estimate

Beat consensus by 32.9% — EPS $0.78 vs $0.5869 estimate

Beat consensus by 36.0% — EPS $0.87 vs $0.6397 estimate

Beat consensus by 14.3% — EPS $0.66 vs $0.5775 estimate

Beat consensus by 6.9% — EPS $1.55 vs $1.4502 estimate

Beat consensus by 9.2% — EPS $0.77 vs $0.7054 estimate

Beat consensus by 10.1% — EPS $1.13 vs $1.0265 estimate

Beat consensus by 18.7% — EPS $0.5 vs $0.4214 estimate

Beat consensus by 18.7% — EPS $0.48 vs $0.4045 estimate

Missed consensus by 5.8% — EPS $1.12 vs $1.1892 estimate

Beat consensus by 7.2% — EPS $1.03 vs $0.9605 estimate

Beat consensus by 5.3% — EPS $0.95 vs $0.9021 estimate

Beat consensus by 23.0% — EPS $0.64 vs $0.5204 estimate

Beat consensus by 68.2% — EPS $0.31 vs $0.1843 estimate

Beat consensus by 35.2% — EPS $0.39 vs $0.2885 estimate

Beat consensus by 77.5% — EPS $1.06 vs $0.5971 estimate

Beat consensus by 35.2% — EPS $2.26 vs $1.6711 estimate

Beat consensus by 6.5% — EPS $1.14 vs $1.0708 estimate

Missed consensus by 19.9% — EPS $0.32 vs $0.3993 estimate

Missed consensus by 38.8% — EPS $0.22 vs $0.3593 estimate

Missed consensus by 19.8% — EPS $0.33 vs $0.4114 estimate

Beat consensus by 14.2% — EPS $0.4 vs $0.3503 estimate

Beat consensus by 12.1% — EPS $0.21 vs $0.1874 estimate

Beat consensus by 17.0% — EPS $0.22 vs $0.1881 estimate

Beat consensus by 13.6% — EPS $121.54 vs $106.9641 estimate

Missed consensus by 12.2% — EPS $67.76 vs $77.1366 estimate

Beat consensus by 19.1% — EPS $2.63 vs $2.2085 estimate

Missed consensus by 10.3% — EPS $1.73 vs $1.9291 estimate

Beat consensus by 13.5% — EPS $3.23 vs $2.8448 estimate

Beat consensus by 11.5% — EPS $2.69 vs $2.4134 estimate

Beat consensus by 14.3% — EPS $2.71 vs $2.37 estimate

OSINT: BT's high-price broadband contract sparks consumer backlash